Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines

Overview

This is a single center, randomized, double-blind and placebo controlled clinical study to evaluate the efficacy and safety of brightening microneedle patch on facial solar lentigines. Subjects who are 30 to 65-year-old with solar lentigines on their faces will receive brightening microneedle patches on facial solar lentigines once a day for 4 weeks. Afterwards, facial images and skin detectors will be used to analysis their skin, according to various skin tone indexes and skin response score sheets.

Full Title of Study: “A Single Center, Randomized, Double-blind and Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 8, 2021

Detailed Description

Method: 35 subjects, Fitzpatrick Skin Type II to IV. Each subject has at least two brown solar lentigines on the face, and the two spots are independent, each with a clear boundary and diameter ≥ 0.5 cm. This trial includes 1 screening visit (Day -1), wash-out period (2 weeks before the trial), trial period (4 weeks in total), and 3 return visits for detecting (baseline detecting at the end of the wash-out period, the 2nd week and the 4th week of the trial period).

Interventions

  • Other: AIVÍA, Ultra-Brightening Spot Micro-needle Patch
    • a dissolving micro-needle patch, contains active ingredients
  • Other: Placebo Micro-needle Patch
    • matching placebo will be provided as a dissolving micro-needle patch

Arms, Groups and Cohorts

  • Experimental: brightening micro-needle patch
    • apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
  • Placebo Comparator: Placebo
    • apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package

Clinical Trial Outcome Measures

Primary Measures

  • the percentage change of skin tone index ITA° value of facial solar lentigines from baseline
    • Time Frame: 4 week
    • measure L* (luminance) and b* (yellow/blue component) values at baseline and 4th week by color meter (CR-400 Chroma Meter) to assess the ITA° percentage change. (ITA°=tangent arc((L*-50)/b*) 180/3.14159)

Secondary Measures

  • the value change of skin tone index ITA° value of facial solar lentigines from baseline
    • Time Frame: 4 week
    • measure L* (luminance) and b* (yellow/blue component) values by color meter (CR-400 Chroma Meter) at baseline and 4th week to assess the ITA° value change. (ITA°=tangent arc((L*-50)/b*) 180/3.14159)
  • the value change of skin tone index ITA° value of facial solar lentigines from baseline
    • Time Frame: 2 week
    • measure L* (luminance) and b* (yellow/blue component) values by color meter (CR-400 Chroma Meter) at baseline and 2nd week to assess the ITA° value change. (ITA°=tangent arc((L*-50)/b*) 180/3.14159)
  • the value change of melanin index of facial solar lentigines from baseline
    • Time Frame: 2 week
    • measure the melanin index by CK Mexameter at baseline and 2nd week
  • the value change of melanin index of facial solar lentigines from baseline
    • Time Frame: 4 week
    • measure the melanin index by CK Mexameter at baseline and 4th week
  • the percentage change of melanin index of facial solar lentigines from baseline
    • Time Frame: 2 week
    • measure the melanin index by CK Mexameter at baseline and 2nd week
  • the percentage change of melanin index of facial solar lentigines from baseline
    • Time Frame: 4 week
    • measure the melanin index by CK Mexameter at baseline and 4th week
  • rating the improvement of facial solar lentigines on the facial image taken by VISIA, skin analysis imaging system
    • Time Frame: 2 week
    • use Physician Global Assessment (PGA) to assess the percentage improvement of lesions using VISIA images , with a scale of -1 to 5
  • rating the improvement of facial solar lentigines on the facial image taken by VISIA, skin analysis imaging system
    • Time Frame: 4 week
    • use Physician Global Assessment (PGA) to assess the percentage improvement of lesions using VISIA images , with a scale of -1 to 5
  • assessing the value change of skin tone index L*a*b* of facial solar lentigines from baseline
    • Time Frame: 2 week
    • determine the facial spot color index L*a*b* by color meter (CR-400 Chroma Meter) at baseline and 2nd week
  • assessing the value change of skin tone index L*a*b* of facial solar lentigines from baseline
    • Time Frame: 4 week
    • determine the facial spot color index L*a*b* by color meter (CR-400 Chroma Meter) at baseline and 4th week
  • assessing the percentage change of skin tone index L*a*b* of facial solar lentigines from baseline
    • Time Frame: 2 week
    • determine the facial spot color index L*a*b* by color meter (CR-400 Chroma Meter) at baseline and 2nd week
  • assessing the percentage change of skin tone index L*a*b* of facial solar lentigines from baseline
    • Time Frame: 4 week
    • determine the facial spot color index L*a*b* by color meter (CR-400 Chroma Meter) at baseline and 4th week
  • assessing the patches safety on the skin by adverse reactions
    • Time Frame: through study completion, an average of 4 weeks
    • assess by the incidence of adverse reactions
  • assessing the patches safety on the skin by subject diary
    • Time Frame: through study completion, an average of 4 weeks
    • assess by subject diary
  • assessing the patches safety on the skin by skin response
    • Time Frame: through study completion, an average of 4 weeks
    • assess by skin response score sheets
  • assessing the subjects’ compliance with the trial by subjects’ return visits
    • Time Frame: through study completion, an average of 4 weeks
    • assess subjects’ compliance by the number of the subjects’ return visits
  • assessing the subjects’ compliance with the trial by subject diary
    • Time Frame: through study completion, an average of 4 weeks
    • assess subjects’ compliance by subject diary
  • assessing the subjects’ compliance with the trial by the number of patches packages returned
    • Time Frame: through study completion, an average of 4 weeks
    • assess subjects’ compliance by the number of patches packages returned by the subjects
  • assessing the subjects’ feedback of the patches
    • Time Frame: through study completion, an average of 4 weeks
    • assess the questionnaire completed by the subjects. Items in the questionnaire include satisfaction, patch usability, patch shape, patch size, skin quality after using the patch, issues with product use, etc.

Participating in This Clinical Trial

Inclusion Criteria 1. Men or women between 30 and 65 years old (inclusive); 2. The PI determines the subject's skin type as Fitzpatrick Skin Type II to IV; 3. The PI's diagnosis is that the subject has at least two brown solar lentigines on the face, and the two spots are independent, each with a clear boundary and diameter ≥ 0.5 cm; 4. The subject can understand and follow the requirements, instructions and restriction of the plan; 5. The subject signs patient consent form in writing. Exclusion Criteria 1. The PI's diagnosis is that the subject has tissue mutation, inflammation or other lesions on the face; 2. Those who have received aggressive facial treatments within the past six months, including laser, IPL, RF (radio frequency), HIFU(high-intensity focus ultrasound), or dermal filler injection; 3. Those with a history of chronic skin diseases or autoimmune diseases, such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo, rosacea, keloid and so forth; 4. Those who have a history of allergies to the product ingredients of the brightening micro-needle patch, the moisturizer or the sunscreen provided by the trial; 5. Pregnant or lactating women; 6. Those who have used facial blemish-lightening products (such as products claiming to have whitening or blemish-lightening effects), topical or oral whitening drugs within 21 days before entering the trial; 7. Those who have smoking habits within 12 months before entering the trial; 8. Those who have used any skin medication on the face within 30 days before entering the trial, determined by the PI to have effect on this study; 9. Those who have participated in other clinical trials within 30 days before entering the trial; 10. Those who are currently undergoing medical treatment and their ability to participate in this trial will be affected; 11. Those who the PI considers to be unsuitable to join this trial.

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Panion & BF Biotech Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.